new group called Cytomix that will deal with the cell analysis. BioSure is our brand which has peptone manufacturing and selling in India. We understood this technology as we were already aligned with partners from Europe. We were giving them inputs and realized why not utilize this knowledge for Indian market.
Q: How is the market competition and have you boosted your presence to tackle it?
Competition is intense if you work as a distributor but when you are a manufacturer with unique set of products, things are different. We have offices in Gurgaon, Delhi, Chandigarh and Hyderabad.
We also have technical teams at Mumbai and Kolkata.
We are moving from research oriented clients to industry due to funding strains that affect their buying power. The patient driven funding areas such as diagnostics are witnessing a lot of attention from our side. We have a balanced portfolio.
Q: What is the growth percentage for biosupplier sector expected in upcoming fiscal year?
The 10 percent growth is expected. I see the good scope in Make in India provided the relevant people get encouragement to manufacture. I feel that we need to utilize the Indian brains sitting outside India. If their ideas are being used by MNCs there to sell us the stuff, why can’ t we do that here?
Q: Have you observed any change in the client behavior since last few years? Are they more demanding?
The expectations have indeed changed over the period of time. While the clientele is more receptive but action on ground is not matching enough. The scientists have been patient but had to look for greener pastures due to lack of options.
While the new bio-clusters have been announced, we need to get it off the ground. The top companies putting their units in such places must not be prioritized.
42 BioVoiceNews | February 2017